Intravitreal Injections of Ziv-aflibercept for Macular Diseases

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2016

Conditions
Diabetic Macular EdemaAge Related Macular DegenerationBranch Retinal Vein Occlusion With Macular EdemaCentral Retinal Vein Occlusion With Macular Edema
Interventions
DRUG

Intravitreal injections of ziv-aflibercept

All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).

Trial Locations (1)

06010-130

Retina Clinic / UNIFESP, São Paulo

All Listed Sponsors
collaborator

Federal University of São Paulo

OTHER

lead

Retina Clinic, Sao Paulo, Brazil

OTHER

NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases | Biotech Hunter | Biotech Hunter